A bill for an act relating to abortions including definitions, informed consent, dispensing of abortion-inducing drugs, and other abortion-related provisions. (Formerly HF 2563, HSB 704.) Effective date: 07/01/2026.
HF 2788 revises Iowa law governing abortion and abortion-inducing drugs. It updates statutory definitions of “abortion” across multiple chapters, clarifying that abortion does not include treatment of miscarriage, removal of products of conception after an incomplete or inevitable pregnancy loss, or treatment of ectopic pregnancy. The bill also repeals chapter 146C and makes related conforming changes to reporting and informed-consent provisions.
The bill adds new informed-consent requirements before an abortion is performed, including an in-person examination by a physician and screening for signs of coercion or abuse. For chemical abortions, it requires the physician to obtain the patient’s signature on the FDA patient agreement form and written acknowledgment of specific risks, follow-up recommendations, and emergency surgical options. It also directs the Board of Medicine to adopt rules and provides that physicians who fail to comply may face license discipline.
HF 2788 substantially restricts the dispensing of abortion-inducing drugs by requiring that they be dispensed directly to the patient in a health care setting by an authorized person. It creates a private civil cause of action allowing an “interested party” to sue for damages if the drug is dispensed in violation of the new restrictions, while also providing privacy protections by requiring redaction of the woman’s identifying information. The bill expressly states that it does not impose civil or criminal liability on the woman who undergoes the chemical abortion.
The bill also expands abortion-related reporting requirements by requiring disclosure of whether mifepristone or misoprostol was used in an induced termination, and whether those drugs were ingested within 14 days before a spontaneous termination of pregnancy. These changes affect health care providers, pharmacies, clinics, hospitals, and physicians, and they create new compliance and reporting obligations under Iowa’s public health and professional licensing laws.
Overall, the bill appears to have been supported by majorities in both chambers, passing the House and Senate and becoming an enacted chapter. The voting history suggests generally favorable sentiment among supporters, while the structure of the bill indicates that the main opposition likely centered on the new chemical-abortion restrictions, private enforcement mechanism, and expanded reporting requirements. The most notable contention points are the direct-to-patient dispensing rule, the private right of action, and the additional informed-consent and documentation mandates for abortion-inducing drugs.
HF 2788 amends Iowa’s abortion statutes in chapters 144, 146A, 146B, 146E, and newly created 146F, while repealing chapter 146C. It imposes new physician examination, informed-consent, dispensing, reporting, and discipline requirements, and creates a private civil enforcement mechanism for violations involving abortion-inducing drugs. The bill directly affects physicians, other licensed health care providers, pharmacies, clinics, hospitals, and patients seeking medication abortion, and it expands the state’s regulatory and enforcement framework for abortion care.
The bill’s enactment and recorded passage votes indicate that it had sufficient support to move through both chambers and become law. The available voting history suggests a generally favorable sentiment among the majority coalition, while the bill’s subject matter and the nature of its restrictions imply meaningful opposition from lawmakers concerned about abortion access, patient privacy, and the use of private litigation to enforce abortion regulations. No committee transcript is available, so the record reflects support and opposition primarily through floor votes rather than detailed debate.
The most significant points of contention are likely the restrictions on dispensing abortion-inducing drugs, especially the requirement that they be dispensed directly to the patient in a health care setting, and the creation of a private cause of action allowing an interested party to sue for damages. Opponents would likely object to the added burdens on medication abortion access, the expanded reporting of mifepristone and misoprostol use, and the requirement to disclose recent use of those drugs in miscarriage reporting. Supporters would emphasize informed consent, patient safety, coercion screening, and tighter oversight of chemical abortions.